We have analyzed 1448 patients with acquired aplastic anemia, grafted between 2005 and 2009, and compared outcome of identical sibling (n=940) vs unrelated donor (n=508) transplants. When compared to the latter, sibling transplants were less likely to be performed beyond 180 days from diagnosis (39%vs 85%), to have a cytomegalovirus negative donor /recipient status (15% vs 23%), to receive anti-thymocyte globulin in the conditioning (52% vs 61%), and received more frequently marrow as a stem cell source (60% vs 52%). Unrelated donor grafts had significantly more acute grade II-IV (25% vs 13%) and significantly more chronic graft versus host disease (26% vs 14%). In multivariate analysis the risk of death of unrelated donor grafts was higher, but not significantly, compared to a sibling donor (p=0.16). The strongest negative predictor of survival was the use of peripheral blood as a stem cell source (p<0.00001), followed by an interval diagnosis-transplant >180 days (p=0.0005), patient age >20 years (p=0.0005), no anti-thymocyte globulin in the conditioning (p=0.003); and donor/recipient cytomegalovirus serostatus, other than negative/negative ( p=0.04). In conclusion, in multivariate analysis, the outcome of unrelated donor transplants for acquired aplastic anemia, is currently not statistically inferior when compared to sibling transplants, although patients are at greater risk of acute and chronic graft versus host disease . The use of peripheral blood grafts remains the strongest negative predictor of survival.
INTRODUCTION
The current standard of care for patients with acquired severe aplastic anemia (SAA), who lack an HLA identical sibling (SIB), calls for a course of immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and cyclosporine 1 . Transplantation from an unrelated donor (UD) is usually considered after failure of at least one course of IST 2 .
This strategy is based on a relatively high risk of complications for UD transplant recipients, such as graft rejection, graft versus host disease (GvHD) and infections [3] [4] [5] .
However, things have changed in recent years, and the outcome of unrelated donor transplants, has significantly improved [6] [7] [8] : this is probably the consequence of better selection of donors by allele matching , changes in the conditioning regimens with the use of fludarabine, with or without low dose total body irradiation (TBI) [9] [10] [11] , and improved supportive care, including better diagnosis and treatment of transplant related infections.
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Improved supportive care has benefited also SIB transplants, although to a lesser extent, as compared to UD transplants 12 : this is because the outcome of SIB transplants was already extremely good especially, but not exclusively 13 in young patients [14] [15] .
Therefore , improved survival is currently seen with both UD and SIB transplant, and the question is how do they compare, this being relevant for treatment strategies in patients with acquired SAA. 
RESULTS
Engraftment and graft vs host disease (GvHD). The cumulative incidence (CI) of engraftment, as identified by a neutrophil count of 0.5 x10^9/L, was 91% for both SIB and UD transplants; median time to neutrophil engraftment was 19 days for SIB (3-75) and 18 days (3-89) for UD ( Table 2 ). The CI of acute GvHD grade II-IV was13% in SIB (95% C.L.
11-15%) and 25% in UD grafts (95%C.L. 21-29%) ;p<0.0001) (Fig.1a) ; the CI of acute GvHD grade III-IV was 5% vs 10% respectively (p<0.0001). The CI of chronic GvHD was 14% in SIB (95% C.L. 12-18) and 26% in UD grafts (95% C.L. 22-31) (p<0.0001) Fig.1b) Causes of death are outlined in Table 2 , in patients receiving SIB or UD grafts: there is a slight excess of deaths due to GvHD, interstitial pneumonia, and infections in patients receiving UD grafts; deaths due to rejections were comparable.
Univariate analysis on survival. A total of 287 deaths were registered. At 3 months survival was 89% (SE=0.8%), at 6 months was 86% (SE=0.9%), at 1 year was 83% (SE=1%) and at 2,3 and 5 years was, respectively, 80%(SE=1.1%), 79%(SE=1.1%) and 78%(SE=1.2%).
The use of PB as a stem cell source resulted in significantly inferior outcome (70%, SE=2%) as compared to BM (83% ,SE=1.6%) , p<0.001 (Fig.2a) (Table 3) .
We then ran a multivariate analysis separately in patients receiving SIB or UD grafts (Table 4) . We show that all predictors had the same effect in SIB and UD patients, with one exception, the interval diagnosis transplant. This was highly significant in SIB (p<0.001) but not in UD grafts (p=0.8), possibly due to a selection bias for very severe patients receiving an early UD graft (Table 4) .
Risk score. Survival of patients stratified in three risk categories , as described in Materials and Methods, is shown in Figure 3a : low risk (n=391), 90%, intermediate risk (n=709) 77% and high risk (n=348) 67%. We then looked at the effect of donor type (SIB, UD) in the 3 groups: there is a significant survival advantage for SIB grafts in low risk patients (Fig.3b) , although the number of UD patients is small (n=46). There is a possibility that this small group represented a selection of patients with very severe aplasia: indeed mortality was 40% for patients grafted within 90 days from diagnosis, 18% for grafts between 91 and 180 days and 15% for transplants beyond 180 days.
In the large intermediate risk group, comprising 50% of the entire patient population, actuarial survival is superimposable (Fig.3c) . There is no significant survival difference in the smaller high risk group (Fig. 3d) 
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DISCUSSION
We have shown in the current study that the outcome of matched UD transplant for acquired SAA is not statistically inferior to SIB transplants, in multivariate analysis, when corrected for patient age, interval between diagnosis and transplant, stem cell source, the use of ATG and donor recipient CMV status. Patients undergoing UD grafts , however, remain at greater risk of acute and chronic GvHD, and this study has not assessed the quality of life of these patients, which may be significantly affected , especially by chronic GvHD. We have also confirmed several predictors of outcome, some of which can be modified, such as the stem cell source and in vivo T cell depletion , and others which cannot be changed, such as patient age.
The role of ATG in the conditioning regimen, although historically often used in SAA to prevent rejection, is controversial, and in a prospective randomized trial, ATG has failed to show a superiority over controls 16 : however it could be a question of numbers, since the survival advantage for ATG in that trial (134 patients) was 6%, and it is 8% in this series (1448 cases), being predictive in both univariate and multivariate analysis. In addition, time from diagnosis to transplant, age, CMV donor/recipient status, and stem cell source, all proved significant predictors, confirming well known data 14 . The effect of different conditioning regimens, TBI or fludarabine based , did not prove significant in multivariate analysis.
Stem cell source has been studied both in sibling transplants 17, 18 , as well as in unrelated donor grafts 19 , including overall almost 3000 patients, and survival of marrow (BM) grafts has always proved superior to G-CSF mobilized peripheral blood (PB), with the exception of one study on a small number of children 20 . We confirm in the present series of 1448 cases, that PB as a stem cell source, when compared to BM, is the strongest negative predictor of survival, both for SIB and UD: when the two donor types are combined together, the actuarial 5 year survival is 83% for BM versus 70% for PB (p<0.00001), and death rate due to GvHD and infections is 7% for BM versus 17% for PB recipients (p<0.0001). When looking at the combined effect of stem cell source and donor type , the use of PB increased the risk of death in SIB patients from 23% to 37% and in UD patients from 29% to 39%. Therefore bone marrow remains the stem cell source of choice, in patients with acquired SAA undergoing a first allogeneic transplant, both from SIB as Therefore, comparison of SIB -UD in the low risk group is probably between elective early SIB transplants and forced early UD transplants.
The recently published guidelines of the EBMT still read "standard front line treatment for acquired SAA patients who do not have an HLA identical sibling, is combined immunosuppressive therapy, with ATG and cyclosporine 1 ". Whether an UD graft may be considered first line therapy in young patients with very severe aplasia, should be tested within a clinical trial, also considering the significant increased risk of acute and chronic GvHD in UD graft recipients.
In conclusion: we believe this study suggests improved outcome of UD grafts for acquired aplastic anemia in recent years, not statistically inferior to SIB grafts, when corrected for confounding variables, and especially time to transplant. This information 8 warrants the early activation of an unrelated donor search for patients lacking an HLA matched sibling. Once an UD has been identified, whether to proceed to an UD transplant, will depend on other considerations, such as the degree of matching between the potential donor and the recipient, the patients age , blood counts , transfusion requirement and performance status. The significant increased risk of acute and especially chronic GvHD in UD transplants, needs to be carefully addressed in prospective national or international studies: one study comparing the use of ATG and alemtuzumab in the conditioning, is being planned within the EBMT. 
Legend for Figures
Figure. 1 . Cumulative incidence of acute (a) and chronic (b) graft versus host disease (GvHD): a higher rate is seen for both , in patients grafted from UD as compared to SIB donors. Figure. 2 . Univariate analysis of survival in patients with acquired aplastic anemia stratified for stem cell source (BM= bone marrow; PB= peripheral blood) (Fig. 2a) , age </ > 20 years , (Fig 2b) ; interval diagnosis transplant (DxTx) </ >180 days (dd) (Fig.2c) and use of antithymocyte globulin (ATG) in the conditioning regimen (Fig. 2d ) Fig.3a) . The effect of donor type (UD vs SIB) is significant in low risk patients (Fig.3b) ; survival is not statistically different in intermediate risk (Fig.3c) and high risk patients (Fig. 3d) .
